2025-08-25 - Analysis Report
Okay, here's an analysis of RXRX (Recursion Pharmaceuticals Inc) based on the data provided. The report is structured to present key figures first, followed by analysis and context.

**RXRX (Recursion Pharmaceuticals Inc) Analysis**

*   **Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -47.06%
*   **VOO Cumulative Return:** 38.83%
*   **Relative Divergence:**
    *   Current Divergence: -85.8
    *   Range: Max 35.8, Min -88.1
    *   Relative Divergence Position: 1.9 (Indicates the current divergence is near the lower end of its historical range relative to VOO.)

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -5.0% | 0.0 | 4.3 |
| 2022-2024  | 0.0% | 73.6% | -30.0% | 0.0 | 2.9 |
| 2023-2025  | 4.0% | 73.6% | -41.0% | 0.0 | 2.1 |

*   **Analysis:** The data indicates RXRX has significantly underperformed the S&P 500. The large negative divergence suggests substantial relative weakness. Alpha is consistently negative, meaning RXRX is underperforming its benchmark (VOO) on a risk-adjusted basis. Beta is 0, indicating that the stock's price is not correlated with the S&P 500. The MDD is very high. The company's market cap has also decreased from 4.3B to 2.1B from 2021 to 2025.

**2. Recent Price Action:**

*   **Current Price:** 4.94
*   **Previous Close:** 4.78
*   **Change:** 3.35%
*   **5-Day Moving Average:** 5.02
*   **20-Day Moving Average:** 5.5095
*   **60-Day Moving Average:** 5.3566

*   **Analysis:** The price increased by 3.35%, closing at 4.94. The stock price is below its 5-day, 20-day, and 60-day moving averages, which generally indicates a downtrend.

**3. Technical Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.3377 (Low Risk)
*   **RSI:** 31.14 (Approaching oversold territory)
*   **PPO:** -1.9482 (Bearish, suggesting the short-term moving average is below the long-term moving average)
*   **Hybrid Signal:** Cash_70%_Sell (Suggests selling 70% of holdings and holding a significant cash position)
*   **Recent (20-day) Relative Divergence Change:** -0.3 (Indicates short-term decline relative to the benchmark)
*   **Expected Return (%):** -1372.2% (Extremely negative, indicating significantly negative expected return compared to the S&P 500 over a long-term investment horizon)

*   **Analysis:** The MRI suggests low market risk overall. The RSI indicates the stock may be oversold, potentially signaling a possible rebound. The PPO confirms a bearish trend. The Hybrid Signal is strongly bearish, recommending a large reduction in holdings. Recent price increase of 3.35% from previous close could be due to unforeseen variable that is not covered in this analysis.

**4. Recent News & Significant Events:**

*   **Summary:** Recent news points to significant developments, discussions by analysts regarding performance, notable volatility, and a call for investors to monitor news closely.

*   **Analysis:** The news indicates that the stock is subject to market attention, potentially due to significant company-specific events or broader market factors. Volatility suggests a degree of uncertainty.

**5. Recent Earnings Analysis:**

| Date       | EPS   | Revenue  |
|------------|-------|----------|
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.5  | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.4  | 0.01 B$  |
| 2025-08-05 | -0.4  | 0.01 B$  |

*   **Analysis:** The company is consistently reporting negative EPS, meaning the company is not profitable. Revenue fluctuates, but overall remains quite low.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-06-30 | $0.92B  | -18.70%  |
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |
| 2024-06-30 | $0.58B  | -16.69%  |

*   **Analysis:** Revenue is inconsistent and generally low. Profit margins are mostly negative, reflecting difficulty in controlling costs relative to revenue. ROE is consistently negative, meaning the company is not generating profits from its equity.

**7. Overall Summary:**

RXRX is currently facing significant challenges. The stock is underperforming the S&P 500 by a wide margin. Financial performance is weak, with negative EPS, inconsistent revenue, negative profit margins, and negative ROE. Technical indicators suggest a bearish trend, although the RSI indicates the stock might be oversold. Recent news suggests heightened volatility and market attention. The recommendation is to significantly reduce holdings, as indicated by the Hybrid Signal. The extremely negative expected return further emphasizes the risks associated with investing in RXRX at this time. Recent price increase of 3.35% from previous close is not consistent with the data, and should be monitored.
